Docetaxel

Generic Name: Docetaxel

Brand Names: Taxotere, Docetaxel Accord, Docetaxel Kabi

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₃NO_₁₄

CAS Number: 114977-28-5

Unique Ingredient Identifier: 699121PHCA

Background: Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication: Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer

Associated Therapies: -

Clinical Trials

A Dose-finding Trial of Hyperthermic Intraperitoneal Docetaxel

Phase 1

Conditions: Hyperthermic Intraperitoneal Chemotherapy

Interventions: Drug: Docetaxel

First Posted Date: 2022-06-08

Last Posted Date: 2022-06-08

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 30

Registration Number: NCT05410483

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Other (Non U.s.), China

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

Phase 2

Recruiting

Conditions: Unresectable Salivary Gland Carcinoma
Recurrent Salivary Gland Carcinoma
Stage IV Major Salivary Gland Cancer AJCC v8
Stage III Major Salivary Gland Cancer AJCC v8
Metastatic Salivary Gland Carcinoma

Interventions: Drug: Docetaxel
Other: Questionnaire Administration
Biological: Trastuzumab Emtansine
Biological: Trastuzumab

First Posted Date: 2022-06-07

Last Posted Date: 2024-11-27

Lead Sponsor: NRG Oncology

Target Recruit Count: 116

Registration Number: NCT05408845

Locations: 🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 116 locations

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Phase 1

Active, not recruiting

Conditions: Esophageal Cancer
Gastric and Gastroesophageal Junction Adenocarcinoma
Solid Tumor
NSCLC
Cervical Cancer
Endometrial Cancer

Interventions: Drug: Afuresertib
Drug: Nab paclitaxel
Drug: Docetaxel
Drug: Sintilimab

First Posted Date: 2022-05-20

Last Posted Date: 2024-10-14

Lead Sponsor: Laekna Limited

Target Recruit Count: 167

Registration Number: NCT05383482

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chengdu, China

and more 2 locations

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: BGB-24714
Drug: Paclitaxel
Drug: Carboplatin
Drug: Docetaxel

First Posted Date: 2022-05-19

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Target Recruit Count: 210

Registration Number: NCT05381909

Locations: 🇦🇺
Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia
🇦🇺
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸
Banner Md Anderson Cancer Center, Gilbert, Arizona, United States

and more 19 locations

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Phase 3

Suspended

Conditions: NSCLC

Interventions: Drug: Poziotinib
Drug: Docetaxel

First Posted Date: 2022-05-18

Last Posted Date: 2024-11-13

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 268

Registration Number: NCT05378763

Locations: 🇺🇸
Bond Clinic, P.A., Winter Haven, Florida, United States

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab
Drug: Cisplatin
Drug: Docetaxel

First Posted Date: 2022-05-17

Last Posted Date: 2024-11-18

Lead Sponsor: Krzysztof Misiukiewicz

Target Recruit Count: 24

Registration Number: NCT05376553

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Other: placebo
Drug: capivasertib
Drug: docetaxel

First Posted Date: 2022-04-27

Last Posted Date: 2024-10-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 1017

Registration Number: NCT05348577

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Phase 1

Completed

Conditions: Gastric Cancer

Interventions: Drug: IN10018
Drug: Docetaxel

First Posted Date: 2022-04-14

Last Posted Date: 2022-11-16

Lead Sponsor: InxMed (Shanghai) Co., Ltd.

Target Recruit Count: 33

Registration Number: NCT05327231

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Anyang Tumor Hospital, Anyang, Henan, China

and more 5 locations